Advertisement
CLLS vs PMVP
Which Stock Would AI Choose? Cellectis S.A. (CLLS) vs. PMV Pharmaceuticals (PMVP) Stock Comparison
Key Takeaways
- Both CLLS and PMVP operate in the biotechnology sector, focusing on innovative therapies, but CLLS emphasizes gene-editing for allogeneic CAR-T cells while PMVP targets p53 mutations in oncology.
- CLLS shows stronger recent momentum with a 196% one-year return and positive clinical data from its Cema-Cel trial, contrasting PMVP's 45% one-year gain amid cash preservation.
- CLLS trades at $4.27 with a $440M market cap and $206M cash, while PMVP is at $1.35 with a $74M market cap, highlighting differing scales and valuations.
- Recent developments include CLLS's pivotal trial interim data and PMVP's NEJM publication on rezatapopt, boosting sentiment for both.
- Analyst targets suggest upside: $8 for CLLS (87% potential) versus median $5.50 for PMVP (307% potential from current levels).
Introduction
This stock comparison examines CLLS and PMVP, two clinical-stage biotechs navigating the dynamic healthcare landscape. Both companies target unmet needs in oncology through advanced therapies—gene-edited CAR-T cells for CLLS and p53-targeted small molecules for PMVP. Traders seeking momentum in biotech catalysts and investors eyeing relative performance in small-cap health stocks will find value here. Amid recent market volatility, their contrasting trajectories in clinical progress, cash positions, and price action offer insights into sector positioning and potential trade-offs in risk-reward profiles.
CLLS Overview and Recent Performance
Cellectis S.A. (CLLS) is a clinical-stage biopharmaceutical firm specializing in gene-editing technologies for allogeneic CAR-T cell therapies (chimeric antigen receptor T-cells, engineered immune cells targeting cancer). Its pipeline includes candidates like BALLI-01 for acute lymphoblastic leukemia and ALPHA3 for large B-cell lymphoma. In recent market activity, CLLS shares have surged, posting a 196% one-year return and 10.67% YTD gain as of April 2026, trading around $4.27 within a 52-week range of $1.33-$5.48. Market cap stands at $440M with $206M in cash supporting operations into 2027.
Sentiment has strengthened following Q4 2025 earnings, which reported $10.58M revenue despite an EPS miss, and pivotal interim data from the Cema-Cel trial underscoring its allogeneic CAR-T platform's potential. Analyst reiterations, like Citizens JMP's Market Outperform at $8, reflect optimism around manufacturing capabilities and milestone payments, driving recent price behavior amid broader biotech interest.
PMVP Overview and Recent Performance
PMV Pharmaceuticals (PMVP), a precision oncology company, develops small-molecule therapies reactivating mutant p53 proteins in solid tumors. Its lead candidate, rezatapopt, targets a common mutation across cancers. Shares trade near $1.35, with a $74M market cap, in a 52-week range of $0.81-$1.88. Recent performance includes a 45% one-year gain and 10.80% YTD, though monthly dips reflect sector pressures.
Key influences include full-year 2025 results with an EPS beat in Q4 (-$0.34 vs. -$0.40 expected) and a New England Journal of Medicine publication on rezatapopt's first-in-human data showing selective p53 reactivation. These developments have supported relative stability, with analysts forecasting a median $5.50 target. Cash burn management bolsters its position, though smaller scale amplifies volatility compared to peers.
Trending AI Robots
Tickeron’s Trending AI Robots page curates 25 top-performing AI trading bots from over 351 total bots, selected by advanced algorithms for their suitability in current market conditions like volatility in biotech and semiconductors. These bots employ diverse strategies—trend following, swing trading, long/short pairs—across timeframes from 5 minutes to 60 minutes, trading thousands of tickers in stocks, ETFs, and crypto. Performance stats shine: annualized returns up to 136.62%, win rates from 53% to 87%, profit factors reaching 10.87, and equity growth examples like $48,782 on select agents. Outperforming the S&P 500 (e.g., +13.76% monthly vs. SPY's +2.59%), they offer risk-managed signals for copy trading. Explore these bots to enhance your strategy across varying styles and sectors.
Head-to-Head Comparison
CLLS and PMVP share biotech exposure but diverge in business models: CLLS's gene-editing enables off-the-shelf CAR-T scalability, contrasting PMVP's small-molecule focus on p53 for tumor-agnostic applications. Growth drivers include CLLS's pivotal trial momentum and partnerships versus PMVP's clinical validation in NEJM.
Recent momentum favors CLLS with superior returns and higher revenue ($79.6M ttm), while PMVP trades at a deeper discount to analyst targets. Risk factors: CLLS faces debt (114% debt/equity) and EPS losses; PMVP contends with cash burn in a micro-cap frame. Market sentiment leans positive for both amid oncology advances, but CLLS's larger cap offers relative stability.
Tickeron AI Verdict
Tickeron’s AI currently favors CLLS due to its trend consistency from clinical catalysts, stronger relative performance (196% vs. 45% one-year), and cash runway supporting near-term milestones. While PMVP shows promise in p53 data and higher upside potential, CLLS's momentum and platform validation position it probabilistically ahead in the current biotech environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLLS is a Hold and PMVP is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLLS’s FA Score shows that 0 FA rating(s) are green whilePMVP’s FA Score has 0 green FA rating(s).
- CLLS’s FA Score: 0 green, 5 red.
- PMVP’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLLS’s TA Score shows that 4 TA indicator(s) are bullish while PMVP’s TA Score has 4 bullish TA indicator(s).
- CLLS’s TA Score: 4 bullish, 6 bearish.
- PMVP’s TA Score: 4 bullish, 4 bearish.
Price Growth
CLLS (@Biotechnology) experienced а +2.01% price change this week, while PMVP (@Biotechnology) price change was +1.90% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.66%. For the same industry, the average monthly price growth was -1.63%, and the average quarterly price growth was +2020.83%.
Reported Earning Dates
CLLS is expected to report earnings on Jul 30, 2026.
PMVP is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Biotechnology (+0.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| CLLS | PMVP | CLLS / PMVP | |
| Capitalization | 324M | 57.1M | 567% |
| EBITDA | -39.82M | -83.53M | 48% |
| Gain YTD | -36.983 | -14.400 | 257% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 68.1M | 0 | - |
| Total Cash | 186M | 93.5M | 199% |
| Total Debt | 86.5M | 293K | 29,522% |
CLLS | ||
|---|---|---|
OUTLOOK RATING 1..100 | 59 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 53 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CLLS | PMVP | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 76% | 1 day ago 78% |
| Stochastic ODDS (%) | 1 day ago 80% | 3 days ago 82% |
| Momentum ODDS (%) | 1 day ago 90% | 3 days ago 88% |
| MACD ODDS (%) | 1 day ago 90% | N/A |
| TrendWeek ODDS (%) | 1 day ago 77% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 86% |
| Advances ODDS (%) | 8 days ago 78% | 6 days ago 76% |
| Declines ODDS (%) | 10 days ago 89% | 10 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 86% |
Advertisement